[Express Train Episode 72] Humasis Develops Immune Analysis Reagent Technology

Humasis focuses on the POCT immunoassay reagent product line, POCT immunoquantitative analyzer product line, and the development of new materials and novel markers within the field of in vitro diagnostics.

The immunoqualitative diagnostic product line is a field that consolidates core technologies. In 2004, it developed the nation's first cardiovascular disease diagnostic reagent product line and secured various clients. Cardiovascular disease testing technology forms one pillar of the multi-quantitative POCT testing product line for cardiovascular diseases. Pregnancy-related diagnostic products are new markers with three international patents registered in the US, Europe, and China.

Since 2018, by completing the first phase of the POCT quantitative business development product line, the company has been aggressively pioneering new markets. It is strengthening overseas networks to shorten the speed of raw material and new product development.

Patent attorney Eom Jeong-han from BLT Patent Law Firm reviewed Humasis's patent and trademark application status.

Listed companies on the domestic stock market disclose patent acquisition facts through the Financial Supervisory Service's electronic disclosure system. However, many stock investors tend to overlook patent disclosures.

Not only patents but also trademark registrations indicate the future direction of listed companies, making them one of the important indicators for assessing future corporate value. Some patent disclosures even act as direct triggers for stock price increases.

It is not easy for general investors to understand the impact on companies through patent disclosures or to check trademark application statuses one by one. Asia Economy, together with patent attorney Eom Jeong-han from BLT Patent Law Firm, is reviewing the patent and trademark application status of listed companies through the 'Express Train.'

The Express Train is an abbreviation for a broadcast that diligently searches for stocks surging due to patents.